Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer

Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer

Abstract The anti-HER2 monoclonal antibody trastuzumab and new derivative formulations are the standard treatment for HER2-positive breast cancer. However, after 1 to 5 years of treatment, some patients acquire resistance to therapy, leading to relapse. The microRNA-449 family members were downregul...

Full description

Saved in:
Bibliographic Details
Main Authors: Ana Lameirinhas, Sandra Torres-Ruiz, Iris Garrido-Cano, Cristina Hernando, María Teresa Martínez, Ana Rovira, Joan Albanell, Sandra Zazo, Federico Rojo, Begoña Bermejo, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Molecular Medicine
Subjects:
Breast cancer
HER2
microRNAs-449
FASN
Trastuzumab
Online Access:https://doi.org/10.1186/s10020-025-01163-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s10020-025-01163-z

Similar Items